What question did this study set out to answer?

To assess the safety, pharmacokinetics, and preliminary efficacy of IL-12 prodrug KGX101 in advanced melanoma.

Abstract CT291: First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activation, promising antitumor activity, and a manageable safety profile in advanced or metastatic melanoma

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial evaluates KGX101's safety and efficacy in advanced melanoma, indicating potential benefits in treatment.

To assess the safety, pharmacokinetics, and preliminary efficacy of IL-12 prodrug KGX101 in advanced melanoma.
Open-label, multicenter Phase 1 study
Enrolled patients with advanced melanoma subtypes
Utilized standard 3+3 design for dose escalation
Analyzed peripheral blood for immune response
Commenced with the optimal biological dose before expansion phase
16 subjects received KGX101 across four dose levels
Most adverse events were grade 1 or 2; serious AEs included leukopenia and elevated liver enzymes
KGX101 showed strong immune response, enhancing T cell function
Out of 10 tumor assessments, 1 partial response and 6 stable disease observed
Observations suggest promising efficacy and manageable safety profile

Guo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark